Open access · CC-BY
via OpenAlex
Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Christopher Kai-Shun Leung, Seraph Tianmin Ren, Poemen P. M. Chan, Kelvin Ho-Nam Wan, Aziz Ka Wai Kam, Gilda Wing Ki Lai, Vivian Sheung Man Chiu, Match W. L. Ko, Ka Fai Cedric Yiu, Marco Yu
Trials · 2022 · ▲ 33 citations
Abstract
BACKGROUND: Whereas lowering the intraocular pressure (IOP) can slow optic nerve degeneration in glaucoma, many patients with glaucoma continue to develop progressive loss in vision despite a significant reduction in IOP. No treatment has been shown to be effective for neuroprotection in glaucoma. We set out to conduct a randomized controlled trial to investigate whether nicotinamide riboside (NR), a nicotinamide adenine dinucleotide precursor, is effective to slow optic nerve degeneration in patients with primary open-angle glaucoma (POAG). We hypothesize that patients treated with NR have a slower rate of progressive retinal nerve fiber layer (RNFL) thinning compared with those treated with placebo. METHODS: This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study including 125 patients with POAG. Patients will be randomized to receive 300 mg NR or placebo for 24 months. Clinical examination, optical coherence tomography imaging of the RNFL, and visual field (VF) test will be performed at the baseline, 1 month, 4 months, and then at 2-month intervals until 24 months. The primary outcome measure is the rate of RNFL thinning measured over 24 months. The secondary outcome measures include (1) time to VF progression, (2) time to progressive RNFL/ganglion cell inner plexiform layer (GCIPL) thinning, and (3) the rate of change of VF sensitivity over 24 months (to investigate neuroprotection) and 1 month (to investigate neuroenhancement). The rates of RNFL thinning and VF sensitivity decline between treatment groups will be compared with linear mixed modeling. Survival analysis will be performed to compare the differences in time from baseline to VF progression and time from baseline to progressive RNFL/GCIPL thinning between treatment groups using Cox proportional hazards models. DISCUSSION: Outcome measures in glaucoma neuroprotection trials have been centered on the detection of VF progression, which may take years to develop and confirm. In addition to addressing whether NR has a neuroprotective/neuroenhancement effect in glaucoma patients, this study will demonstrate the feasibility of studying neuroprotection in a relatively short trial period (24 months) by comparing the rates of progressive RNFL thinning, a more reproducible and objective outcome measure compared with VF endpoints, between treatment groups. TRIAL REGISTRATION: Chinese Clinical Trial Registry 1900021998.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s13063-021-05968-1
- Canonical
- link ↗
- Fetched
- 2026-11-04 MST
Cite this
APA
Leung, C.K., Ren, S.T., Chan, P.P.M., Wan, K.H., Kam, A.K.W., Lai, G.W.K., Chiu, V.S.M., Ko, M.W.L., Yiu, K.F.C., & Yu, M. (2022). Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial. <em>Trials</em>. https://doi.org/10.1186/s13063-021-05968-1
Vancouver
Leung CK, Ren ST, Chan PPM, Wan KH, Kam AKW, Lai GWK, et al. Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial. Trials. 2022. doi:10.1186/s13063-021-05968-1.
BibTeX
@article{christopher2022Nicoti,
title = {Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial},
author = {Christopher Kai-Shun Leung and Seraph Tianmin Ren and Poemen P. M. Chan and Kelvin Ho-Nam Wan and Aziz Ka Wai Kam and Gilda Wing Ki Lai and Vivian Sheung Man Chiu and Match W. L. Ko and Ka Fai Cedric Yiu and Marco Yu},
journal = {Trials},
year = {2022},
doi = {10.1186/s13063-021-05968-1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Udine 2024
Open access · US-GOV
Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration (VERA-nAMD).
Trials 2023
Open access · CC-BY
Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial
University Health Network, Toronto 2014
Open access · US-GOV
Progression of Geographic Atrophy and Intravitreal Injections of Ranibizumab Among Treated for Age-related Macular Degeneration
Rishi Singh 2012
Open access · US-GOV
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
Abdulkadir Küçük 2026
Open access · US-GOV
Prospective Evaluation of Blepharoptosis Development in Patients Undergoing Repeated Intravitreal Anti-VEGF Injections
Shahid Beheshti University of Medical Sciences 2018
Open access · US-GOV